Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,361
datasets available to search
ShareScore release 0.9.0
Dataset results
3,361 results for “Randomized Controlled Trial”
Effectiveness of Using 2D Atlas and 3D PDF as a Teaching Tool in Anatomy Lectures in Initial Learner Medical Students: A Randomized Controlled Trial
<p><strong>Dataset Info</strong></p> <p><strong>1) Immediate Test</strong></p> <p># The first row of the dataset identifies the columns.<br> # The first column represents the participant ids.<br> # The second column represents the participants' assigned group.<br> # The third column represents represents the genders of participants (1: Female, 2: Male)<br> # The fourth column represents the years of participants' in their six-year-long medical schools (1: Year-1 students, 2: Year-2 students).<br> # The fifth column represents participants' repeating year status. (0: No, 1: Yes)<br> # The sixth to the fifteenth columns (liver_q1_max2points to liver_q10_max2points) represent the scores in the first to tenth questions of the liver test. Maximum points of the questions can be seen on the first row of the relevant column.<br> # The sixteenth column (livertotalscore_max20points) represents the total score in the liver test.<br> # The seventeenth to the thirty fifth columns (genitalia_q1_max3points to genitalia_q19_max2points) represent the scores in the first to nineteenth questions of the genitalia test. Maximum points of the questions can be seen on the first row of the relevant column.<br> # The thirty sixth column (genitaliatotalscore_max40points) represents the total score in the genitalia test.</p> <p> </p> <p><strong>2) Delayed Test</strong></p> <p># The first row of the dataset identifies the columns.<br> # The first column represents the participant ids.<br> # The second column represents the participants' assigned group.<br> # The third column represents represents the genders of participants (1: Female, 2: Male)<br> # The fourth column represents the years of participants' in their six-year-long medical schools (1: Year-1 students, 2: Year-2 students).<br> # The fifth column represents participants' repeating year status. (0: No, 1: Yes)<br> # The sixth to the fifteenth columns (liver_q1_max2points to liver_q10_max2points) represent the scores in the first to tenth questions of the liver test. Maximum points of the questions can be seen on the first row of the relevant column.<br> # The sixteenth column (livertotalscore_max20points) represents the total score in the liver test.<br> # The seventeenth to the thirty fifth columns (genitalia_q1_max3points to genitalia_q19_max2points) represent the scores in the first to nineteenth questions of the genitalia test. Maximum points of the questions can be seen on the first row of the relevant column.<br> # The thirty sixth column (genitaliatotalscore_max40points) represents the total score in the genitalia test.</p>
Safety and immunogenicity of heterologous booster immunization with Ad5-nCoV after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults: a randomized, double-blind, parallel-controlled trial
<p>Data on safety and immunity of heterologous booster (fourth dose) after three-dose priming with inactivated SARS-CoV-2 vaccine are limited in Chinese adults. Here, we evaluate the safety and immunogenicity of immunization with Ad5-nCoV in a randomized, double-blind, parallel-controlled phase 4 clinical trial in Zhejiang, China (NCT05373030). Participants aged 18-80 years (100 participants per group) who have administered three doses of inactivated SARS-CoV-2 vaccine ≥ 6-month earlier were enrolled and randomized at 1:1 into two groups, then administered intramuscular Ad5-nCoV or different inactivated SARS-CoV-2 vaccine (CoronaVac or Covilo) respectively. All observed adverse reactions were predictable and manageable. Ad5-nCoV elicited significantly higher RBD-specific IgG levels, with a GMC of 2924.0 on day 14 post-booster, 7.8-fold that of the inactivated vaccine. Pseudovirus-neutralizing antibodies to Omicron BA.4/5 showed a similar pattern, with GMT of 228.9 in the Ad5-nCoV group and 65.5 in the inactivated vaccine group. The Ad5-nCoV booster-maintained a high antibody levels on day 90, with seroconversion of 71.4%, while the inactivated vaccine group was 5.2%, closed to pre-booster levels. In summary, a fourth Ad5-nCoV vaccination following three-dose inactivated SARS-CoV-2 vaccination is immunogenic, tolerable, and more efficient than inactivated SARS-CoV-2 vaccine. Ad5-nCoV elicits a stronger humoral response against Omicron BA.4/5 and maintains antibody levels for longer than homologous boosting.</p>
Data from: Identifying and overcoming breastfeeding challenges using two-way short message service, a randomized controlled trial
<p>Breastfeeding challenges, such as pain and perception of insufficient milk supply, prevent many women from exclusively breastfeeding their babies for the six-month duration recommended by the World Health Organization. Mobile health strategies may help women identify and overcome breastfeeding challenges. This study evaluated a two-way short message service (SMS) intervention that delivered breastfeeding messages to women in Kiambu County, Kenya, and its impact on rates of exclusive breastfeeding and breastfeeding behavior at 1, 4, and 6 months post-delivery. Women in the control group received a general package of messages containing postnatal information; women in the intervention group received these messages, plus messages related to breastfeeding and surveys which offered more information about breastfeeding challenges. Both groups of women had access to a help desk agent who responded to questions via SMS.</p> <p>There was no significant difference in the rate of exclusive breastfeeding between the intervention and control at any time point (p=.861). Women in the intervention group were more likely to report experiencing breastfeeding challenges such as pain and perceived insufficient milk supply than those in the control group (32% vs. 24%, p=0.00). Of the women in the intervention group who reported experiencing breastfeeding challenges, 70% of them found a resolution to their challenge, and 23% of them resolved their challenges using SMS. SMS may help women in low-resource settings to identify and overcome their breastfeeding challenges.</p>
Leukocyte- and Platelet-Rich Fibrin in endoscopic endonasal skull base reconstruction: study protocol for a multicenter prospective, parallel-group, single-blinded randomized controlled non-inferiority trial.
<p>Instruction video on how to prepare Leukocyte- and Platelet-Rich Fibrin for endoscopic endonasal skull base reconstruction reinforcement. </p>
Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage
ClinicalTrials.gov study NCT01787123. IPD Sharing: Not stated. Countries: 1. Publications: 1.
TADCLOT- a Double Blind Randomized Controlled Trial
ClinicalTrials.gov study NCT06318481. IPD Sharing: NO. Countries: 1. Publications: 2.
Designing a Smoking Intervention for Youth Smokers Using Q-Methodology: A Pilot Randomized Controlled Trial
ClinicalTrials.gov study NCT07178899. IPD Sharing: YES. Countries: 1. Publications: 23.
A Pilot Clinical Trial of Sympathetic Blockade With Botulinum Toxin Type A to Treat Complex Regional Pain Syndrome (CRPS): a Randomized, Double-Blind, Controlled, Crossover Trial.
ClinicalTrials.gov study NCT00637533. IPD Sharing: Not stated. Countries: 1. Publications: 1.
An Randomized Double Blind Controlled Trial of niPGT-A in Women With RPL
ClinicalTrials.gov study NCT05685147. IPD Sharing: NO. Countries: 1. Publications: 12.
Randomized Controlled Double Blind Trial of Short vs Long Acting Dihydrocodeine in Chronic Non-malignant Pain
ClinicalTrials.gov study NCT00547885. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial
ClinicalTrials.gov study NCT00120978. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Rotational Thromboelastometry Guided Blood Component Use in Children With Cirrhosis Undergoing Invasive Procedures: A Randomized Controlled Trial
ClinicalTrials.gov study NCT04460222. IPD Sharing: NO. Countries: 1. Publications: 1.
Efficacy of Electro-acupuncture for Abdominal Obesity: Study for a Randomized Controlled Trial
ClinicalTrials.gov study NCT04957134. IPD Sharing: NO. Countries: 1. Publications: 23.
Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Ta
ClinicalTrials.gov study NCT02132299. IPD Sharing: Not stated. Countries: 1. Publications: 2.
The Effect of Music and Environmental Noise Isolation on Bronchiolitis Severity in Hospitalized Children: a Randomized Control Trial
ClinicalTrials.gov study NCT04833686. IPD Sharing: NO. Countries: 1. Publications: 33.
What Needle Diameter Should Physician Use When They Perform Lumbar Puncture ? A Randomized Controlled Trial
ClinicalTrials.gov study NCT01481922. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Antenatal Vitamin D3 Supplementation in Bangladesh: Randomized Controlled Trial
ClinicalTrials.gov study NCT01126528. IPD Sharing: Not stated. Countries: 1. Publications: 5.
A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients
ClinicalTrials.gov study NCT01452399. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Effectiveness of Percutaneous Electrolysis in the Treatment of Lateral Epicondylalgia. A Single-Blind Randomized Controlled Trial.
ClinicalTrials.gov study NCT03225404. IPD Sharing: Not stated. Countries: 1. Publications: 4.
A Randomized Control Trial of an Intervention to Reverse Frailty and Enhance Resilience Through Exercise and Education
ClinicalTrials.gov study NCT04628754. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.